1,720,991 research outputs found
Peripheral neuropathy in hepatitis C virus-related mixed cryoglobulinaemia: existing treatments and a positive symptomatic response to oxcarbazepine.
No full textDELIRIUM IN VASCULAR DEMENTIA: CHOLINESTERASE INHIBITION AS A POSSIBILE THERAPY. A CONTROLLED, OPEN 24-MONTH STUDY IN 246 PATIENTS.
No full text
A new MAPT deletion in a case of speech apraxia leading to corticobasal syndrome
No full textSpeech apraxia is a disorder of speech motor planning/programming leading to slow rate, articulatory distortion, and distorted sound substitutions. We describe the clinical profile evolution of a patient presenting with slowly progressive isolated speech apraxia that eventually led to the diagnosis of corticobasal syndrome (CBS), supporting the evidence that this rare speech disorder can be the first presentation of CBS. Moreover, we found a novel variant in MAPT gene, which is hypothesized to be disease-causing mutation. These results underscore the importance of genetic analysis–particularly in selected atypical cases–for in vivo understanding of possible pathophysiological disease process
Risks of cerebrovascular events in the treatment of behavioral symptoms in vascular dementia.
No full textCOGNITIVE IMPAIRMENT IN LATERALIZED PHENOTYPE OF CORTICOBASAL DEGENERATION.
No full textCorticobasal degeneration (CBD) is a rare disorder, which normally includes a combination of neurobehavioural features, movement disorders and other manifestations. It is now recognized that CBD patients usually present with two phenotypes: the lateralized phenotype and the dementia phenotype. The aim of our work was to determine the nature and the progression of cognitive and behavioural impairment in 10 lateralized CBD patients. In our patients, the most salient aspects of cognitive impairment were: an evident alteration of rapid alternating operative strategies, associated with the evident impairment of set shifting, of executive operations, of operative and sequential procedure and of implementation of judgement and abstract reasoning. The self-activation of retrieval processes is partly preserved in CBD. As all the other types of subcortical impairments, even CBD encompasses both cognitive impairment as well as a wide range of behaviour disturbances, such as progressive alteratio
PAINFUL PERIPHERAL NEUROPATHY ASSOCIATED WITH HEPATITIS C. A REVIEW OF THE TREATMENT AND A POSITIVE RESPONSE TO OXCARBAZEPINE.
No full textPOSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME VS CEREBRAL SINUS THROMBOSIS: A SINGLE CASE REPORT IN A POSTPARTUM WOMAN.
No full text
OLANZAPINE AS A POSSIBLE TREATMENT OF BPSD IN VASCULAR DEMENTIA: RISK OF CEREBROVASCULAR EVENTS.
No full textAbstract: Behavioral problems produce excess disability, potentially devastating in cognitively impaired patients. These behavioral symptoms can be a major cause of stress, anxiety and concern for caregivers. While psychotropic drugs are frequently used to control these symptoms, they have the potential for significant side effects, which include sedation, disinhibition, depression, falls, incontinence, parkinsonism and akathisia. We followed up (for 12 months) a group of 346 consecutive outpatients, with a diagnosis of subcortical vascular dementia or multi-infarctual dementia. Patients eligible for this open-label study were required to have behavioral problems (BPSD). Patients were divided into two groups, Group A received olanzapine 2.5-7.5 mg/day while Group B received typical antipsychotics. Patients in both groups were allowed to continue any previous therapy. Patients in both groups were significantly improved in their BPSD. Our patients had a host of medical conditions and re
- …
